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ABSTRACT 
Broadly defined, aortitis refers to inflammation of the aorta and incorporates both infectious 
and non-infectious aetiologies. As advanced imaging modalities are increasingly incorporated 
into clinical practice the phenotypic spectrum associated with aortitis has widened. The 
primary large vessel vasculitides, giant cell arteritis and Takayasu arteritis, are the most 
common causes of non-infectious aortitis. Aortitis without systemic disease or involvement of 
other vascular territories is classified as clinically isolated aortitis. Periaortitis, where 
inflammation spreads beyond the aortic wall, is an important disease subset with a distinct 
group of aetiologies. Infectious aortitis can involve bacterial, viral, or fungal pathogens and, 
while uncommon, can be devastating. Importantly, optimal management strategies and patient 
outcomes differ between aortitis subgroups highlighting the need for a thorough diagnostic 
work-up. Monitoring disease activity over time is also challenging as normal inflammatory 
markers do not exclude significant vascular inflammation, particularly after starting treatment. 
Additional areas of unmet clinical need include clear disease classifications and improved 
short- and long-term management strategies. Some of these calls are now being answered, 
particularly with regards to large vessel vasculitis where our understanding has advanced 
significantly in recent years. Work extrapolated from temporal artery histology has paved the 
way for targeted biologic agents and, although glucocorticoids remain central to the 
management of non-infectious aortitis, these may allow reduced glucocorticoid-reliance. 
Future work should seek to clarify disease definitions, improve diagnostic pathways and 






'Aortitis’ refers to inflammation of the aorta. The primary large vessel vasculitides, giant cell 
arteritis (GCA) and Takayasu arteritis (TAK), are the most common non-infectious causes. A 
number of systemic inflammatory diseases have also been implicated including IgG4-related 
disease. Although rare, infectious aortitis must always be considered. Regardless of cause, 
aortitis is associated with significant morbidity.1, 2 As tissue diagnosis is rarely possible, 
differentiating aortitis from other pathologies, including atherosclerosis, remains challenging. 
Here, vascular imaging may be helpful. Once aortitis is confirmed, correctly identifying the 
disease subtype is a further challenge. This review will address these challenges, outline 
current best practice and look towards future possibilities for patients with aortitis.  
 
AETIOLOGY & CLINICAL PRESENTATION  
Accurate disease classification is vital in aortitis. It influences investigation and management, 
and longer-term disease monitoring and prognosis. Sub-acute bacterial aortitis, for example, 
requires intensive short-term antimicrobial treatment but would not typically recur in the long-
term. In contrast, aortitis in a patient with TAK usually requires immunosuppression and a 
lifetime of disease monitoring. The aetiologies of aortitis are discussed below and in Table 1. 
 
Infectious aortitis 
Infectious aortitis is important as symptoms may be non-specific and outcomes catastrophic. 
As its presentation may mimic non-infectious aortitis, a high index of suspicion is critical to 
avoid exposing these patients to immunosuppression. Infection can occur via haematogenous 
spread or directly from neighbouring structures. Pre-existing pathology such as 
atherosclerosis or aneurysm can increase risk, and men are more commonly affected than 
women.3 Salmonella sp. is the most commonly isolated pathogen, with Staphylococcus and 
Streptococcus sp. also frequently implicated.3 Tuberculous, fungal, and syphilitic infections 
are now rare in most healthcare settings. The term mycotic aneurysm was initially used in 
reference to the mushroom-like appearance of bacterial aortic aneurysms, as opposed to an 
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aneurysm of fungal origin as the name implies. This term is now more generally applied to any 
infection-related aneurysm, which constitute 2-3% of all aortic aneurysms.4 Co-existing 
bacteraemia is found in >50% of cases, with evidence of isolated infection elsewhere (most 
commonly endocarditis) in 50%.5  
 
Non-infectious aortitis  
Pathological assessment at time of thoracic aortic surgery demonstrates aortitis in 3-6% of 
surgical specimens.1, 6 Interestingly, the majority of patients in these series had no evidence 
of systemic disease at time of surgery.  
 
Large vessel vasculitis (LVV) 
LVV comprises GCA and TAK. Often distinguishable by age at onset, these conditions share 
many clinical and histological similarities.7 Increasing availability of high-definition vascular 
imaging has led to a global rise in the prevalence of LVV.8 A lack of universally-accepted 
disease definitions means that some use the term LVV for any non-infectious cause of aortitis. 
We suggest reserving this term for those with either GCA or TAK. 
 
GCA 
Previously considered a condition of the cranial arteries (classically the temporal arteries), 
evidence from imaging studies, autopsy series, and mounting clinical vigilance now suggest 
a spectrum of medium and large vessel inflammation, with involvement of the aorta and its 
primary branches in ~50% of patients.9, 10 The terms cranial-GCA (C-GCA), large-vessel-GCA 
(LV-GCA) and C-GCA with LV involvement have been adopted by the European League 
Against Rheumatism (EULAR) to reflect this (Figure 1).11  
 
GCA almost exclusively affects those over the age of 50 with incidence rising with age.12 It is 
commonest in those of Northern European heritage with an incidence of ~20/100,000 
population in Northern Europe and USA.13, 14 Women are more commonly affected than men 
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(3:1),12, 14 although GCA associated with aortitis affects a younger group than classic C-GCA 
with a higher female predominance.15  
 
The clinical features of GCA depend on the vascular territories involved. Aortic involvement is 
often heralded by constitutional symptoms (fever, weight loss, lethargy) and may exist with or 
without classical cranial features. Often a late feature of the disease, the risk of aortic 
aneurysm formation in GCA is ~2-fold higher than in matched controls, with the risk of thoracic 
aortic aneurysm ~6-fold higher.16 Aneurysm growth rate is also increased, with a higher growth 
rate associated with increased risk of dissection.10  
 
TAK 
TAK affects a younger population than GCA (median age of onset ~35 years) and is therefore 
associated with years of cumulative morbidity.17 Again, women are more commonly affected 
(6:1).17, 18 Historically considered to be more prevalent in Asia, similar incidence rates of 
~2/million have been demonstrated in Japan and the US.19, 20 The most comprehensive UK 
study to date has reported incidence and prevalence rates of 0.8/million and 7.5/million, 
respectively. Interestingly, 62% of the 142 patients included were aged >40 years at time of 
diagnosis.21 Although this may reflect diagnostic delay, it casts further doubt on the notion of 
TAK exclusively affecting those <40 years. 
 
Most cases of TAK involve inflammation of one or more aortic segments, often in combination 
with branches such as carotid, subclavian or renal arteries (Figure 1). In a large French series 
of 318 patients with TAK, 78% had involvement of at least one aortic region at time of 
imaging.17 The remaining 22% demonstrated inflammation of aortic branches only.  
 
Previously termed ‘pulseless disease’, patients with TAK may present with unilateral loss of 
pulses or symptoms of limb ischaemia. Hypertension is common, either as a consequence of 
renal artery involvement or due to stenotic or occlusive portions of the aorta (Figure 2).22 
Cardiac decompensation may occur with aortic root involvement or increasing afterload.17 
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Clinically isolated aortitis (CIA) 
Aortitis may exist without clinical or histopathological evidence of systemic disease, or 
involvement of other vascular territories. Historically termed isolated aortitis, idiopathic aortitis, 
or non-syndromic aortitis, ‘clinically isolated aortitis’ (CIA) has been the preferred term since 
2015.5 The 2012 Revised International Chapel Hill Consensus Conference Nomenclature of 
Vasculitides considers CIA a single-organ vasculitis, and distinct from LVV – although this 
distinction is not universally upheld.23 Compared with GCA and TAK, few studies have sought 
to characterise CIA. 
 
Many of the available demographic data about CIA come from pathological studies, usually 
following aortic aneurysm resection.1, 24 These suggest the ascending aorta is most commonly 
affected, although this may reflect surgical practice rather than the underlying disease 
process. More recently, radiologically-defined CIA has become increasingly prevalent with 
clinical series suggesting that the aortic arch and descending thoracic aorta are more 
commonly affected.25 This distinction aside, the demographics of patients with pathologically- 
or radiologically-defined CIA are similar, with a female predominance and a peak age of onset 
in the 7th decade.1, 25, 26 Given the similarities with GCA, many have questioned whether CIA 
might be the first presentation of a systemic vasculitis – either not clinically evident at 
presentation or overlooked. Additionally, some suggest that IgG4-related disease may account 
for a significant proportion of isolated thoracic aortitis.27 Indeed, ~20% of patients with CIA will 
go on to develop an associated inflammatory condition, most commonly GCA, and thus be re-
classified.1 Accordingly, many consider CIA a provisional diagnosis, and clinicians should 
entertain a high index of suspicion that additional clinical features may develop.   
 
As most cases of CIA are either asymptomatic or present non-specifically, prevalence 
estimates are limited and it is likely that a significant proportion are undiagnosed.1 The most 
robust studies of those found to have aortitis at time of aortic aneurysm repair suggest that 
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CIA accounts for ~70%, though this likely overestimates the contribution of CIA to aortitis as 
a whole.1, 6  
 
Aortitis associated with other inflammatory conditions 
Aortitis may be a manifestation of several other inflammatory conditions detailed in Table 2.  
 
Periaortitis 
When inflammation extends beyond the aortic wall into the periaortic space it is termed 
‘periaortitis’. The distinction between aortitis and periaortitis is important as underlying disease 
processes, diagnostic considerations, treatments and complications differ markedly. Some 
overlap exists, most notably for IgG4-related disease which causes both. Periaortitis may be 
idiopathic or secondary (Table 1). The clinical picture is variable and patients may present 
with constitutional symptoms in association with abdominal or lower back pain. Clinical 
manifestations due to compression of adjacent structures including lymphatics, retroperitoneal 
vasculature and ureters should not be overlooked (Figure 3). 
 
DISEASE TRIGGERS & HISTOLOGICAL PATTERNS OF INFLAMMATION 
Recent work has deepened our understanding of the pathogenesis of LVV, the most common 
form of aortitis. Innovative mouse models now replicate aortic inflammation and genome-wide 
association studies are deciphering the genetic basis for both GCA and TAK.28 29, 30 Despite 
these advances, specific disease triggers remain largely unknown. Both autoantibody (anti-
endothelial cell antibodies) and infectious (Mycobacterium sp,, Chlamydia pneumoniae and 
varicella zoster virus) triggers have been postulated.31, 32  However, many of these studies 
examined temporal artery tissue and findings may not extrapolate to the aorta. In case-control 
studies, environmental triggers, including smoking and asbestos exposure, have been linked 
with retroperitoneal fibrosis.33 
 
Different histological patterns of aortic inflammation have been described (Figure 4 & Table 
2). Granulomatous inflammation is most common and is seen in GCA, TAK and the majority 
 8 
of CIA. Two distinct inflammatory leucocyte-cytokine signatures have been defined within this 
pattern.1 28 The early inflammatory response, isolated to the vessel wall, is mediated by the 
interleukin(IL)-6/Th17/IL-17 pathway. The IL-12/Th1/interferon(IFN)-γ signature promotes 
sustained inflammation and vascular smooth muscle cell proliferation. Current biologic agents 
can target several key components of both pathways including IL-6 (tocilizumab), IL-12 
(ustekinumab) and T-cell activation (abatacept). Janus kinase (JAK) inhibitors have also 
demonstrated efficacy in preclinical and preliminary clinical trials.34 
 
DIAGNOSIS & DISEASE MONITORING 
Short of histological examination (which is rarely available), there exist no robust diagnostic 
criteria for aortitis. Thus, distinguishing aortitis from other disease mimics (like atherosclerosis) 
relies on a combination of clinical judgement and interpretation of imaging and laboratory 
studies (Figure 5). Long-term disease monitoring, including discriminating active inflammation 
from established vascular sequelae, presents a further challenge. 
 
Laboratory markers 
Studies in biopsy-proven GCA suggest that the inflammatory markers C-reactive protein 
(CRP) and erythrocyte sedimentation rate (ESR) are almost universally raised at diagnosis.35 
However, a study of 196 patients with histologically-confirmed aortitis at time of aneurysm 
repair found that in those with CIA (n=129), mean CRP and ESR were within the normal 
range.1 CRP and ESR are also less likely to be raised in TAK and are less reliable markers of 
disease activity once immunosuppression has started.36 Novel markers such as matrix 
metalloproteinases-3 and -9, and pentraxin-3 may be more specific to large vessel 
inflammation and discriminate active aortitis from other pathology, although further studies are 




Aortic wall thickening, often used as a surrogate marker of inflammation, can be identified 
using computed tomography (CT), magnetic resonance imaging (MRI) or ultrasound (US). 
However, this is not specific for vasculitis and can reflect vascular damage or vascular 
inflammation.39 CT- and MR-angiography will assess luminal abnormalities, including 
dilatations and stenoses. MR-angiography also provides information about mural 
enhancement, a marker of aortic inflammation with sensitivity approaching 90% in TAK.40 
Vessel wall oedema, almost always present in active aortitis but which may persist following 
inflammation resolution,39 is more readily identified with MRI than CT and does not require 
contrast. Both mural enhancement and oedema may provide useful distinctions between 
aortitis and atherosclerosis. The functional map of inflammation provided by positron emission 
tomography (PET), usually with 18F-Fluorodeoxyglucose (FDG), provides a valuable 
assessment of aortic and associated large vessel inflammation. Used in conjunction with CT 
(PET/CT) or MRI (PET/MR), vascular FDG uptake can identify inflammation not otherwise 
visible (Figure 6).41 Meta-analysis has demonstrated pooled sensitivities and specificities of 
90% and 98% for GCA, and 87% and 73% for TAK.42 However, PET is not perfect as other 
aortic pathology (including atherosclerosis) may demonstrate patchy low-grade FDG uptake. 
Additionally, higher costs, longer procedure times and greater radiation exposure are 
unavoidable. Radiation exposure can be reduced with PET/MR, which has demonstrated 
promising diagnostic potential.43 Future aortitis imaging will incorporate novel PET 
radiotracers, some of which may predict complications.44, 45 
 
All imaging modalities discussed have a role in periaortitis. US may be sufficient to establish 
abdominal aortic wall thickening or aneurysm with an associated periaortic infiltrate and is also 
useful in assessing ureteric obstruction. CT and MR provide a more definitive assessment, 
often demonstrating homogenous fibrotic tissue encompassing the distal aorta and iliac 
vessels with or without compressive complications (Figure 3).46 
 
Distinguishing between aortitis subtypes 
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Clinical features, patient demographics and an ‘aortitis screen’ may help discriminate aortitis 
aetiology (Figure 5 & Table 3). Imaging helps with diagnostic uncertainty. CT- or MR-
angiography should be the initial investigation of choice with imaging extended from the 
carotid bifurcation to the iliac arteries as the distribution of other abnormal vascular segments 
will provide diagnostic clues (Figure 1).11 These may also help distinguish infectious and non-
infectious causes as infection is likelier to demonstrate peri-aortic and soft tissue fluid or gas 
accumulation with mycotic aneurysms. Within the aorta, location and disease extent can 
distinguish disease subtypes (Table 2 & Figure 2). Additional PET imaging is useful if 
symptoms and signs do not align with CT or MRI findings. Although rarely performed in aortitis, 
CT-guided biopsy may be valuable in some patients with periaortitis, allowing distinction 
between IgG4-related disease, Erdheim-Chester disease and lymphoma, with clear 
implications for management. In the case of apparently ‘refractory’ inflammatory disease, the 
possibility of infectious aortitis should be reconsidered.  
 
Disease monitoring 
Long-term disease monitoring is critical to identify active disease, detect vascular 
complications, and guide intervention. This can be challenging as symptoms may be absent, 
or, if present, may relate to either established vascular abnormalities or clinically active 
disease. In LVV, the benefit of disease monitoring to accurately match disease activity with 
treatment intensity is well established. Radiological and surgical follow-up data for those with 
CIA suggest grumbling, subclinical aortic inflammation is common with an increased rate of 
future aortic events compared with matched populations.25, 47 Accordingly, even without 
symptoms, most centres advocate radiological aortitis monitoring at least annually.1 
 
Despite its importance, disease-monitoring tools are limited. Any imaging modality described 
can be used, however each has limitations. This is an area of unmet clinical need and novel 
scanning techniques such as PET/MR may provide a way forward.43 Emerging MRI contrast 
agents, such as ultra-small superparamagnetic particles of iron oxide, can be taken up by 
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aortic wall-resident macrophages and may provide surrogate markers of inflammatory 
activity.48 
 
OUTCOMES & PROGNOSIS 
Aortitis is not benign and prognosis depends upon underlying cause. Some patients may have 
a ‘single-hit’ non-recurring illness if treated appropriately. In others, an inability to match 
treatment intensity with disease activity may lead to unchecked subclinical disease 
progression, relapse or side-effects of over-treatment. In GCA, the presence of aortitis (LV-
GCA) is associated with a poorer prognosis than classical C-GCA.15 
 
Aortic complications 
Aortic dissection, aneurysm or rupture contribute to morbidity and mortality. The existing data 
– reporting aortic complication rates of ~5-50% – come from surgical series following-up 
patients who have undergone aortic aneurysm repair.24, 47 It is difficult to draw firm conclusions 
from such studies due to significant heterogeneity in disease definition and monitoring.  
 
Some have tried to discriminate complication rates between aortitis phenotypes. Miller et al 
compared outcomes in 45 patients found to have aortitis at ascending aortic resection. They 
found no difference in aortic complication rates between CIA (n=21) and LVV (n=20) after a 
follow-up of 83 months.24 Clifford et al reported outcomes from 196 patients with histologically-
proven aortitis following thoracic surgery.1 The majority (66%) were originally classified as 
CIA. During a follow-up of 56 months, 44% developed new vascular lesions and 40% 
underwent additional vascular surgery with no difference between CIA and LVV.  
 
Growing evidence discriminates outcomes in those diagnosed radiologically as opposed to 
histologically. Such studies are more representative of the general aortitis population and in-
keeping with our current disease understanding. Ferfar et al examined outcomes in 353 
patients diagnosed with aortitis either histologically or radiologically.2 After a follow-up of 52 
months, aortic aneurysm occurred in 21%, 25% and 43% of patients with GCA, TAK and CIA, 
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respectively. Aortic dissection occurred in 5%, 2% and 10%. Interestingly, the poorer 
outcomes in CIA versus LVV occurred despite similar rates of glucocorticoid treatment. The 
existing data support a need to monitor patients with aortitis for future aortic complications, 
particularly in those with CIA who may experience higher rates of new aortic lesions despite 
fewer symptoms.2  
 
Other sources of morbidity 
Smouldering aortic inflammation can be associated with systemic upset. In a US TAK cohort 
(median age 27 years at diagnosis), >60% had difficulty with daily activities, and 23% were 
unable to work due to disability.22 Population level studies have demonstrated an increased 
risk of ischaemic heart disease, stroke and peripheral vascular disease in those with LVV 
versus matched healthy controls.49 As such, primary cardiovascular disease prevention should 
be part of management. Evidence for antiplatelet use in the absence of cardiovascular disease 
is limited and decisions should be taken on an individual patient basis.50 
 
Mortality 
In-hospital mortality rates of 21-44% have been reported for infectious aortitis, usually due to 
sepsis.51 Non-infectious aortitis is associated with much lower mortality. In the study by Ferfar 
et al, 7.6% of patients with aortitis had died after 52 months.2 This equates to a reported 5-
year survival for CIA, TAK and GCA of 86%, 100% and 88%, respectively. Mortality has been 
mostly studied in GCA, with conflicting results. However, data do consistently support an 
increased mortality in those with aortic disease.52 Although rare, the mortality associated with 
ruptured aortic aneurysm due to GCA (80%) is higher than in those without GCA (65-75%).53 
 
MANAGEMENT 
Non-infectious aortitis may benefit from immunosuppression but management of aortitis 
associated with other inflammatory conditions is usually determined by the underlying 
condition, and not by the presence of aortitis (Table 2). The management of infectious aortitis 
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involves targeted and prolonged anti-microbial therapy, often in combination with surgical 
intervention.   
 
Management of LVV 
Glucocorticoids remain the cornerstone of treatment of both GCA and TAK. Almost all patients 
will receive high dose oral prednisolone (1 mg/kg/day) following diagnosis. A prolonged 
glucocorticoid taper is typical, targeting ≤5 (GCA) or ≤10 (TAK) mg/day by 1 year or earlier.54 
The presence of aortitis and other large vessel involvement in GCA is associated with higher 
cumulative glucocorticoid exposure compared with classical C-GCA.15 Although effective, 
glucocorticoids have significant side-effects occurring in ~90% of patients.55 Accordingly, 
glucocorticoid-sparing agents, both biologic and non-biologic, are an increasingly important 
part of LVV management. Guidelines suggest a glucocorticoid-sparing agent in combination 
with prednisolone as first-line management in TAK and in those with refractory or relapsing 
GCA.54 Again, those with LV-GCA more frequently require glucocorticoid-sparing therapy than 
those with C-GCA alone.15  
 
Tocilizumab, a humanised monoclonal antibody which inhibits IL-6, is licensed for use in GCA 
in Europe and the US following the landmark GiACTA (Giant Cell Arteritis Actemra) study.56 
In 251 randomised patients, GiACTA demonstrated lower cumulative glucocorticoid exposure 
and higher rates of sustained remission at 1 year in those treated with tocilizumab plus 
glucocorticoids versus glucocorticoids and placebo. Questions remain regarding tocilizumab 
use in LVV, including difficulties with disease monitoring and masking active disease.57 
Additionally, the majority of those recruited to GiACTA had C-GCA without evidence of aortitis.  
 
Although limited evidence supports the use of other glucocorticoid-sparing agents in LVV, in 
our practice methotrexate and mycophenolate mofetil have proven useful.58, 59 Biologic agents 
such as ustekinumab and abatacept target key pathways involved in generating aortic 
inflammation and have shown promise in early clinical trials.60, 61 
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Management of CIA 
This remains controversial. Patients with isolated histological aortic inflammation at time of 
aneurysm resection are unlikely to be symptomatic. In this group, treatment is directed at 
preventing future aortic events. Studies do not universally support the use of glucocorticoids, 
particularly as significant cumulative glucocorticoid exposure would be required to prevent a 
relatively rare event, but more evidence is required.1, 25 Those with CIA diagnosed 
radiologically are perhaps more likely to present with non-specific symptoms which could be 
attributed to aortic inflammation. Such patients may benefit from immunosuppression but, 
again, opinion is divided. As such, treatment decisions should be taken on an individual patient 
basis, taking into consideration symptom burden, disease extent and perceived likelihood of 
progression. Few data inform the latter, although being male may be associated with an 
increased risk of future events.2 Glucocorticoids are probably the treatment of choice in this 
setting, however, other agents such as azathioprine, cyclophosphamide, methotrexate and 
tocilizumab have been used.1, 25  
 
Management of periaortitis 
Most causes of periaortitis, including retroperitoneal fibrosis and IgG4-related disease, are 
glucocorticoid sensitive. In glucocorticoid-refractory cases, cyclophosphamide and, more 
recently, rituximab, potentially in combination with methotrexate or mycophenolate mofetil, 
have shown promise.62, 63  
 
Surgical and endovascular intervention 
Aortic dissection and aneurysm formation/rupture are feared complications of aortitis. Surgical 
and endovascular interventions are potential options here, regardless of underlying aetiology. 
Ideally, any surgical intervention should be performed during disease remission. When this is 
not possible, ‘pre-treatment’ with immunosuppression may be useful. Aneurysm repair in 
patients with aortitis is typically performed as an open procedure, however, endovascular 
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Aortitis is increasingly recognised in the clinic. Accurate diagnosis and disease monitoring are 
critical for optimal management.  Identifying those patients in whom potentially life-threatening 
complications might develop is an area of unmet clinical need. Novel vascular imaging 
techniques provide potential tools to differentiate aortitis from aortopathy, identify disease 
subtypes and to monitor inflammation over time. Although treatment options are improving for 
LVV, the most common form of aortitis, the optimal management for CIA remains unclear. 
This will be important to address as almost half of those diagnosed with CIA will develop new 
lesions and progress. Improving disease definitions and providing clarity regarding the 
phenotypic spectrum of aortitis may help to eliminate heterogeneity in clinical practice. Global 
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Table 1. Causes of aortitis 
 Infectious Aortitis 
 Bacterial  
o Most commonly Salmonella, Staphylococcus,  




 Large vessel vasculitis  
o Giant cell arteritis 
o Takayasu arteritis 
 Clinically isolated aortitis 
 Aortitis associated with alternative inflammatory conditions 
o Ankylosing spondylitis 
o Behçet’s disease 
o Cogan's syndrome 
o Granulomatosis with polyangiitis 
o IgG4-related disease  
o Relapsing polychondritis 
o Rheumatoid arthritis 
o Sarcoidosis 
o Systemic lupus erythematosus 
Periaortitis 
 Histiocytosis (Erdheim-Chester disease) 
 Idiopathic 
o Inflammatory abdominal aortic aneurysm 
o Retroperitoneal fibrosis 
 IgG4-related disease  
 Neoplastic 
 Radiotherapy 
IgG4, immunoglobulin G4. 
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Table 2. Histological, topographic and clinical features associated with aortitis subtypes 
 
 
Condition Prevalence of aortitis Histology & typical aortic involvement Clinical features 
Ankylosing spondylitis Aortic involvement in 20-80%, 
although prevalence of aortitis 
specifically unknown65  
Lymphoplasmacytic; 
Aortic valve & root  
Symptoms of spinal inflammation +/- extra-
articular involvement including uveitis, 
psoriasis, colitis  
Behçet’s disease <10%66 Mixed inflammatory; 
Saccular pseudoaneurysms, thoracic & 
abdominal aorta 
Recurrent oral and genital ulceration +/- GI, 
neurological, joint, skin, eye disease 
CIA 100% Granulomatous/giant cell or 
lymphoplasmacytic; 
Thoracic aorta  
May be asymptomatic or present with non-
specific symptoms, or symptoms related to 
aortic complications 
Cogan's syndrome ~10%5 Mixed inflammatory; 
Aortic valve 
Interstitial keratitis and vestibulo-auditory 
dysfunction 
GCA ~30-80%9, 10 Granulomatous/giant cell; 
See Figure 1 
Constitutional symptoms +/- limb claudication, 
cranial symptoms including visual 
disturbance, PMR 
GPA Uncommon Granulomatous/giant cell with extensive 
necrosis & neutrophil involvement; 
Thoracic & abdominal aorta 
Constitutional symptoms +/- evidence of 
specific organ involvement (eg. kidney, lung, 
ENT, nerve, skin) 
IgG4-RD 6-36%67, 68  Lymphoplasmacytic and/or periaortitis, IgG4+ 
plasma cells present; 
Thoracic & abdominal aorta 
Development of sub-acute mass typically 
involving salivary glands, autoimmune 
pancreatitis, retroperitoneal fibrosis 
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Infectious aortitis 100% Suppurative (bacterial) or 
granulomatous/giant cell 
(mycobacterial/fungal); 
Mycotic aneurysms, areas of previous aortic 
damage/disease 
Fever, abdominal pain, back pain, features of 
infection elsewhere 
RA 1-5%5, 69 Granulomatous/giant cell; 
Aortic valve +/- thoracic/abdominal aorta 
Classical articular + extra-articular features of 
RA; aortitis more common if other features of 
rheumatoid vasculitis present 
Relapsing polychondritis Aortic disease in ~10% 
although active aortitis 
uncommon70 
Mixed inflammatory; 
Aortic valve & root  
Largely cartilaginous inflammation involving 
ears, nose, eyes, joints and respiratory tract 
Sarcoidosis Uncommon Granulomatous/giant cell with non-caseating 
granulomas, or lymphoplasmacytic; 
Thoracic & abdominal aorta 
Respiratory symptoms (or incidental 
radiological abnormalities) +/- constitutional 
symptoms, skin involvement, 
lymphadenopathy, uveitis  
SLE Uncommon Lymphoplasmacytic; 
Thoracic & abdominal aorta 
Wide-ranging. Constitutional symptoms +/- 
arthralgia, Raynaud’s phenomenon, skin rash, 
pulmonary disease, renal disease, 
haematological disease, cardiac disease  
TAK ~80%17  Granulomatous/giant cell; 
See Figure 1 
Constitutional symptoms +/- pulse 
discrepancies, hypertension, limb 
claudication, cardiac insufficiency 
CIA, clinical isolated aortitis; ENT, ear, nose and throat; GCA, giant cell arteritis; GI, gastrointestinal; GPA, granulomatosis with polyangiitis; 
IgG4-RD, immunoglobulin G4-related disease; PMR, polymyalgia rheumatica; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; 
TAK, Takayasu arteritis. 
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Table 3. ‘Aortitis screen’ laboratory investigations 
Investigation Interpretation 
FBC Useful baseline investigation;  
Leucocytosis, thrombocytosis and/or anaemia may reflect inflammation or 
infection 
Kidney function Useful baseline investigation; 
Kidney function may be abnormal in GPA, SLE, sarcoidosis, and with any 
involvement of renal arteries (eg. in TAK) 
Liver function Useful baseline investigation 
CRP Likely to be elevated at diagnosis regardless of cause of aortitis; 
May be suppressed once treatment initiated despite ongoing disease 
activity 
ESR Likely to be elevated regardless of cause of aortitis; 
May be suppressed once treatment initiated despite ongoing disease 
activity 
Serum calcium May be elevated in sarcoidosis 
Serum 
immunoglobulins 
May be elevated in sarcoidosis; 
Total IgG & IgE may be elevated in IgG4-RD; 
IgG4 elevated in ~2/3 of patients with IgG4-RD;71 
Those with aortitis as a manifestation of IgG4-RD may have lower levels of 
IgG4 than those without aortic involvement72 
Serum complement C3 & C4 may be reduced in SLE & IgG4-RD 
Serum ACE Limited value & non-specific, but may be elevated in sarcoidosis 
ANA May be positive in SLE, RA & other inflammatory conditions 
ANCA Positive in 90% with GPA73 
RF Reported sensitivity of 69% & specificity of 85% in RA;74 
In those with rheumatoid aortitis, RF positivity may be higher (>85%)75 
Anti-CCP antibodies Reported sensitivity of 67% & specificity of 95% in RA74 
HLA-B27 Positive in ~90% with AS but non-specific76; 
Not a routine screening test but useful if AS strongly suspected 
Blood culture Necessary investigation to help exclude infectious aortitis 
Syphilis serology Useful if syphilis suspected or history of disease 
Tuberculosis testing Necessary if suspicion of active or latent tuberculosis 
ACE, angiotensin converting enzyme; ANA, antinuclear antibodies; anti-CCP, anti-cyclic 
citrullinated peptides;  ANCA, anti-neutrophil cytoplasmic antibodies; ANCA, anti-neutrophil 
cytoplasmic antibodies; ANCA, anti-neutrophil cytoplasmic antibodies; AS, ankylosing 
spondylitis; C3/4, complement component 3/4; CRP, C-reactive protein; ESR, erythrocyte 
sedimentation rate; FBC, full blood count; GPA, granulomatosis with polyangiitis; HLA-B27, 
human leucocyte antigen-B27; IgG, immunoglobulin G; IgE, immunoglobulin E; IgG4-RD, 
immunoglobulin G4-related disease; RA, rheumatoid arthritis; RF, rheumatoid factor; SLE, 
systemic lupus erythematosus; TAK, Takayasu arteritis. 
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Figure 1. Classification of giant cell arteritis and Takayasu arteritis. Patterns of disease 
involvement such as those demonstrated here may help to differentiate LVV from mimics such 
as atherosclerosis which cause a more diffuse pattern of injury.  
C-GCA, cranial giant cell arteritis; LV-GCA, large vessel giant cell arteritis; TAK, Takayasu 
arteritis. 
 
Figure 2. MR-angiography showing 3D reconstructed images of vascular involvement in two 
patients with Takayasu arteritis. The red arrow denotes an area of mid-aortic stenosis.  
 
Figure 3. Red arrows denote an area of fibrotic tissue encompassing the abdominal aorta with 
compression of the iliac arteries and of the right ureter leading to hydronephrosis of the right 
kidney in a patient with periaortitis. Biopsy revealed a dense B cell infiltrate with granulomatous 
inflammation. The patient responded well to rituximab. 
 
Figure 4. The four main histological forms of aortitis. Granulomatous inflammation, the most 
commonly observed pattern, is seen in GCA, TAK and the majority of CIA. A 
lymphoplasmacytic pattern of inflammation may be seen with several inflammatory conditions 
such as ankylosing spondylitis and systemic lupus erythematosus. This is also typical of 
periaortitis in IgG4-related disease. Behçet’s disease may present a mixed inflammatory 
picture, as may Cogan’s syndrome and relapsing polychondritis. A suppurative pattern is 
typical of bacterial infection, most commonly due to Salmonella, Staphylococcus or 
Streptococcus sp. 
VSMCs, vascular smooth muscle cells. 
 
Figure 5. Flow diagram – a potential approach to the diagnosis of aortitis subtypes. 
CTA, computed tomography angiography; MRA, magnetic resonance angiography; PET, 
positron emission tomography; BP, blood pressure; RA, rheumatoid arthritis; SLE, systemic 
lupus erythematosus; ANCA, anti-neutrophil cytoplasmic antibodies; PMR, polymyalgia 
rheumatica; C-GCA, cranial giant cell arteritis; TB, tuberculosis; FBC, full blood count; U&E, 
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urea & electrolytes; LFTs, liver function tests; CRP, C-reactive protein; ESR, erythrocyte 
sedimentation rate; ANA, antinuclear antibodies; RF, rheumatoid factor; anti-CCP, anti-cyclic 
citrullinated peptides; ACE, angiotensin converting enzyme; IgG4, immunoglobulin G4; US, 
ultrasound; CIA, clinically isolated aortitis; LVV, large vessel vasculitis; TAK, Takayasu 
arteritis; GCA, giant cell arteritis.  
 
Figure 6. (A) PET/CT image showing inflammation isolated to the ascending aorta. (B) CT 
angiography image showing thickening and contrast enhancement of the wall of the ascending 
aorta.  Although disease mimics such as atherosclerosis can cause increased FDG uptake in 
the aortic wall, circumferential high-grade FDG uptake combined with wall thickening, as 
demonstrated here, is more likely to be a consequence of aortitis.  
 
